Orteronel

From WikiMD.org
Jump to navigation Jump to search

Orteronel (pronounced: or-ter-o-nel) is a non-steroidal antiandrogen that was under development for the treatment of prostate cancer. It was developed by Takeda Pharmaceutical Company but its development was discontinued in 2014.

Etymology

The term "Orteronel" does not have a known etymology. It is a coined term used to represent this specific drug.

Pharmacology

Orteronel selectively inhibits 17,20-lyase, an enzyme which is necessary for the production of androgens in the body. Androgens are hormones that play a role in male traits and reproductive activity. It is these hormones that can stimulate the growth of prostate cancer cells. By inhibiting the production of these hormones, Orteronel can slow the growth of these cells.

Clinical Trials

Orteronel was studied in phase III clinical trials for the treatment of patients with metastatic, castration-resistant prostate cancer. However, the trials did not meet their primary endpoint of improved overall survival and the development of the drug was discontinued.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski